floridatoday.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.
Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on floridatoday.com
Excerpt from:
Hauppauge High School held a ceremonial ribbon-cutting of legacy trees, honoring the classes of 2022, 2023 and 2024 who were impacted by the coronavirus. (Courtesy of Hauppauge School District)
HAUPPAUGE, NY Hauppauge High School held its Legacy Tree Ceremony in the school's front circle on Monday, honoring the classes of 2022, 2023 and 2024, the students of which were impacted by the coronavirus pandemic, the school district announced.
As part of the tradition, trees were planted and dedicated to each class that had their high school careers impacted by the coronavirus.
Subscribe
Two years ago, Hauppauge High School held a ceremony for the class of 2021, and next year, a ceremony will be held with trees donated to the classes of 2020 and 2025.
The district thanked Carmela Primiani, Judith Olaechea and Julie Misciagna of the PTSA for spearheading this effort to honor students impacted by the pandemic. The district also thanked the Hauppauge Educational Foundation and President Fred Pitrelli for their "continued generosity and support of the students in Hauppauge Public Schools."
Here is the original post:
Legacy Trees Honor Hauppauge High Schoolers Impacted By Coronavirus - Patch
The years of social distancing and wearing masks daily are behind us but that doesn't mean the virus that prompted it all has disappeared.
EAU CLAIRE (WQOW) - The years of social distancing and wearing masks daily are behind us but that doesn't mean the virus that prompted it all has disappeared.
The Eau Claire City County Health Department is monitoring waste water data to determine where trends are with Covid. Their Communicable Disease Specialist, Rachel Mukai, said we are currently seeing a slight increase in Covid activity both at a state and national level.
"One of the possible factors that might be causing this slight increase is the new FLiRT variant also referred to as the KP variant of Covid. The FLiRT variant has not been shown to cause more severe disease, but because it is a new variant it does come with some increased spread," said Mukai.
Although we remain at a low level for Covid in local waste water, there are still things she recommends people due to stay healthy. Washing hands often, staying home when sick, moving large gatherings outside when weather permits, and getting your vaccines.
She said anyone six months and older can receive a booster shot. If you're feeling sick she recommends taking an at home Covid test.
For Eau Claire Covid-19 waste water data, click here.
Have a story idea? Let us knowhere
Read this article:
Eau Claire City County Health Department seeing slight uptick in Covid cases - WQOW TV News 18
delawareonline.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.
Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on delawareonline.com
Read this article:
Fall 2024 COVID-19 vaccine to target rising group of variants - The News Journal
Watch CBS News
COVID-19 cases are surging across the U.S. with the CDC saying a new variant is growing or likely growing in 43 states. Dr. William Schaffner, a professor at the Vanderbilt University School of Medicine, joined CBS News to talk about the rise in cases.
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.
See more here:
More Videos
Next up in 5
Example video title will go here for this video
Next up in 5
Example video title will go here for this video
A total of 39 states are seeing a rise in COVID cases. Ohio remains stable, although the Buckeye State is seeing a slow uptick in case numbers.
Author: wkyc.com
Published: 4:43 PM EDT July 2, 2024
Updated: 4:43 PM EDT July 2, 2024
Go here to see the original:
image:
Colorized scanning electron micrograph of a cell (blue) infected with the Omicron strain of SARS-CoV-2 virus particles (pink), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland.
Credit: NIAID
A Phase 1 trial testing the safety of an experimental nasal vaccine that may provide enhanced breadth of protection against emerging variants of SARS-CoV-2, the virus that causes COVID-19, is now enrolling healthy adults at three sites in the United States. The National Institutes of Health (NIH) is sponsoring the first-in-human trial of the investigational vaccine, which was designed and tested in pre-clinical studies by scientists from NIHs National Institute of Allergy and Infectious Diseases (NIAID) Laboratory of Infectious Diseases.
The rapid development of safe and effective COVID-19 vaccines was a triumph of science, and their use greatly mitigated the toll of the pandemic, said NIAID Director Jeanne M. Marrazzo, M.D., M.P.H. While first-generation COVID-19 vaccines continue to be effective at preventing severe illness, hospitalizations, and death, they are less successful at preventing infection and milder forms of disease. With the continual emergence of new virus variants, there is a critical need to develop next-generation COVID-19 vaccines, including nasal vaccines, that could reduce SARS-CoV-2 infections and transmission.
The study aims to enroll 60 adult participants, ages 18 to 64 years old, who previously received at least three prior doses of an FDA-approved or -authorized mRNA COVID-19 vaccine. The trial sites are Baylor College of Medicine, Houston; The Hope Clinic of Emory University, Decatur, Georgia; and New York University, Long Island. Hana M. El Sahly, M.D., at the Baylor College of Medicine Vaccine Research Center, is leading the study.
Study volunteers will be divided into three cohorts. Those in the first cohort will receive one dose of the investigational vaccine delivered in a nasal spray at the lowest dosage, with enrollees in the next two cohorts receiving progressively higher doses. During seven follow-up visits over about one year, scientists will measure how well the vaccine candidate is tolerated, and if it generates an immune response in the blood and in the nose.
The investigational vaccine, MPV/S-2P, uses murine pneumonia virus (MPV) as a vector to deliver a version of the SARS-CoV-2 spike protein (S-2P) stabilized in its prefusion conformation. MPV does not cause disease in humans or non-human primates but does have an affinity for epithelial cells that line the respiratory tract and may be effective in delivering vaccine to the places where natural coronavirus infections begin.
In pre-clinical non-human primate studies, MPV/S-2P was safe and well tolerated. It produced robust systemic immune responses, including SARS-CoV-2-directed antibodies, as well as local immunity in cells in the mucosal tissues lining the nose and respiratory tract. Studies in humans and animals suggest that mucosal immunity is more effective than systemic immunity in controlling replication of respiratory viruses.
This is the first NIAID clinical trial to be conducted as part of the U.S. Department of Health and Human Services (HHS) Project NextGen. Led by the Biomedical Advanced Research and Development Authority, part of the HHS Administration for Strategic Preparedness and Response, and NIAID, Project NextGen is a coordinated effort between the federal government and the private sector to broaden the pipeline of new, innovative vaccines and therapeutics. Through Project NextGen, NIAID plans to facilitate clinical development of promising next-generation COVID-19 vaccines in Phase 1 and 2 trials.
More information about the trial is available at clinicaltrials.gov using the identifier NCT06441968.
NIAID conducts and supports researchat NIH, throughout the United States, and worldwideto study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
NIH...Turning Discovery Into Health
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
Continued here:
NIH-sponsored trial of nasal COVID-19 vaccine opens - EurekAlert
More Videos
Next up in 5
Example video title will go here for this video
Next up in 5
Example video title will go here for this video
Right now, at least 44 states are seeing an uptick in cases.
Author: 13newsnow.com
Published: 12:15 PM EDT July 2, 2024
Updated: 12:15 PM EDT July 2, 2024
Go here to see the original:
COVID-19 cases rising with new 'FLIRT' variant - 13newsnow.com WVEC
(WXYZ) Summer has brought a fresh wave of COVID-19 infections. Case levels have been rising for weeks due to new variants, leading to increased emergency department visits and deaths.
According to the Centers for Disease Control and Preventions COVID-19 data tracker, emergency department visits have risen by 23.3% and deaths have increased by 14.3% in the most recent week.
Data from the sewage tracking system WastewaterSCAN shows that this summer's COVID-19 wave started earlier than last year and has now reached levels similar to last summers peak.
Since the virus loves warm, humid weather, its spreading the most in the Western and Southern parts of the U.S. right now. In fact, viral levels in the West are as high as they were back in February.
Now, the increase in cases is likely due to a family of variants descended from the JN.1 variant, nicknamed FliRT. This name refers to where these variants changed amino acids.
Their mutations help them dodge the bodys immune response and spread more easily. According to CDC data, two of these variants, KP.3 and KP.2, now make up more than half of new COVID-19 infections in the U.S.
Initially, the Food and Drug Administration approved a plan to update the COVID-19 shots to be more effective against the JN.1 lineage but later advised manufacturers to target the KP.2 strain as it gained more ground.
The new vaccines are expected to be ready sometime in mid-August to late September. Once available, the CDC recommends that people 6 months and older get the updated COVID-19 vaccine for the 2024-25 season.
Thats because as research shows, vaccine effectiveness does wane over time. And even though COVID-19 is always circulating at some level, getting vaccinated in the fall offers the best protection for most people during the colder months when we tend to see higher and longer peaks of infections.
As for the summer peak, COVID-19 can still surprise us since its known to be unpredictable. So, we'll have to wait and see if cases continue to rise or level off. To lower your chances of getting sick, the CDC advises staying up to date on vaccinations, washing your hands well and staying home if you feel sick. Wearing a mask is also smart.
Though no mask is perfect, studies show that high-quality masks can filter out particles, lowering your risk of catching COVID-19 because its reducing how much virus you might breathe in around you.
View original post here:
COVID-19 cases on the rise this summer due to new variants - WXYZ 7 Action News Detroit
Coronavirus is back in the headlines as the calendar flips to July.
Federal officials estimate COVID-19 infections are on the rise in 43 states, including Michigan, though viral tracking isnt as efficient as it was during the height of the pandemic.
An estimated 23 states have growing infection rates, based on daily emergency department visits for COVID-19. Another 20 states have rates that are probably growing, according to the U.S. Centers for Disease Control and Prevention.
The viral infection that took the world by storm in 2020 accounted for less than 1% of emergency department visits in the U.S. for Jun 16 to June 22. Those visits were up 23% from the previous week, according to the Centers for Disease Control and Prevention (CDC).
Focusing on Michigan, data from the state health department indicates little change week-over-week.
Michigans reported infections have remained consistent for at least two months. The week ending June 22 included 807 reported COVID-19 cases, which wasnt far from the 813 cases reported the week ending April 20.
Trips to the emergency room and urgent care centers for COVID account for less than 1% of visits, which has been the case since mid-March. The 12 COVID deaths from the week ending June 15 fell into the typical range (4 to 20) since late March.
Related: CDC ends 5-day isolation time for those who test positive for COVID-19
In recent weeks, infections have generally been higher in the south and out west. Summer upticks have been common in recent years as hot temperatures push residents back indoors where viral transmission is more likely.
The highest rates of tests coming back positive for COVID belong to Region 9 (California, Nevada, Arizona and Hawaii) and Region 10 (Washington, Oregon, Idaho, and Alaska).
Hawaii had the highest percentage of emergency department visits with COVID last week (5%), followed by Florida (1.8%), Washington (1.6%), Arizona (1.6%), New Mexico (1.6%), and Alaska (1.5%).
The CDC is recommending everyone ages 6 months and older receive a yet-to-be-released COVID-19 vaccine this fall to protect against severe illness. The new shot will ideally target the KP.2 strain of omicron, which accounted for about 21% of cases as of June 22.
Our top recommendation for protecting yourself and your loved ones from respiratory illness is to get vaccinated, said CDC Director Dr. Mandy Cohen in a prepared statement. Make a plan now for you and your family to get both updated flu and COVID vaccines this fall, ahead of the respiratory virus season.
More than 6.3 million Michigan residents have gotten at least one does of a COVID-19 vaccine, accounting for about 63% of the population. About 12.5% of residents got the latest booster, which was made available fall 2023.
Originally posted here:
COVID is climbing in the U.S. What about Michigan? - MLive.com
